Semaglutide – 30mg

Semaglutide (often designated in laboratory settings as GLP-1 SM) is a synthetic, long-acting analog of the human incretin hormone Glucagon-Like Peptide-1 (GLP-1). It features a 94% sequence homology to native human GLP-1, strategically modified at position 8 (alanine substituted with alpha-aminoisobutyric acid) to provide complete resistance against rapid dipeptidyl peptidase-4 (DPP-4) enzymatic breakdown. Furthermore, it is acylated with a hydrophilic spacer and a C18 fatty diacid chain at position 26. This allows for high-affinity, reversible binding to endogenous albumin, extending its biological half-life to approximately 165 hours. It serves as a primary tool in metabolic research for evaluating glycemic control, appetite pathways, and cardiovascular biomarkers in advanced animal models.

Key Features & Characteristics

• Mechanism of Action: Acts as a highly potent, selective GLP-1 receptor agonist that mimics natural incretin signaling pathways to influence metabolic homeostasis.
• Structural Optimization: Amino acid substitutions isolate the peptide chain from immediate plasma protease destruction, vastly outlasting native GLP-1.
• Extended Pharmacokinetics: The integrated C18 fatty diacid sidechain minimizes renal clearance, sustaining stable baseline receptor engagement over prolonged experimental windows.
• Physical Form: Produced via high-fidelity recombinant DNA or solid-phase synthesis and supplied as a sterile-filtered, ultra-pure white lyophilized powder.

Primary Research Applications

• Appetite Regulation & Satiety Dynamics: Heavily studied in neuroendocrine research to chart how the compound targets the arcuate nucleus in the hypothalamus and hindbrain centers to suppress caloric intake and delay gastric emptying rates.
• Pancreatic & Glycemic Balance: Investigated in glucose-tolerance assays to observe glucose-dependent insulin secretion upregulation and concurrent glucagon suppression within pancreatic islet cells.
• Cardiovascular & Hepatic Tissue Models: Evaluated in preclinical studies to monitor its secondary effects on lowering inflammatory biomarkers, reducing systemic lipid accumulation, and protecting myocardial cells against ischemic stress.

For Research Use Only. Not for human consumption, therapeutic, or diagnostic use.